TABLE OF CONTENTS

CERTIFICATION ..... **ii**
DEDICATION ..... **iii**
DECLARATION ..... **iv**
ACKNOWLEDGEMENTS ..... **v**
RESUMÉ ..... **xi**
1 CHAPTER ONE **1**
INTRODUCTION AND LITERATURE REVIEW **1**
1.1 Onchocerciasis (River blindness) 1
1.2 The Parasite (*Onchocerca volvulus*) 2
1.2.1 Taxonomy and morphology 2
1.2.2 The life cycle of *O. volvulus* 3
1.3 The Disease 5
1.3.1 The Distribution 5
1.3.2 Clinical Manifestations 7
1.3.3 Molecular Pathology of onchocerciasis 13
1.3.4 Diagnosis of the disease 15
1.4 Immunology/Immunopathology in Onchocerciasis 19
1.4.1 Immunity to onchoccerciasis 19
1.4.2 Immune Responses in Onchocerciasis 20
1.5 Disease prevention and control 24
1.5.1 Control through nodulectomy 25
1.5.2 Vector control 25
1.5.3 Control through chemotherapy 26
1.5.4 Development of new drugs 29
1.6 Global Programs for Onchocerciasis Control 32
1.6.1 Onchocerciasis control program (OCP) 33
1.6.2 Onchocerciasis Elimination Program for the Americas (OEPA) 34
1.6.3 African program for onchocerciasis control (APOC) 35
1.7 Expanded Special Project for the Elimination of NTDs (ESPEN) 37
1.8 Conceptual framework for onchocerciasis elimination in Africa with IVM-MDA 38

1.8.1 Brief Description of the conceptual framework 38
1.8.2 Brief Description of the conceptual framework phases 39
1.8.3 Time needed to eliminate the disease 41
1.9 Assessment of CDTI Programs 43
1.10 Monitoring Onchocerciasis Control Program strategies 44
1.11 Vaccine development 45
1.12 Epitope prediction and synthetic peptides in diagnosis 47
1.13 Bioinformatics in Target Discovery 47
1.14 Protein characterisation and the role of anti-GPCR antibodies 48
1.15 RNA interference in drug discovery 50
1.16 Application of RNAi in *Onchocerca volvulus* studies 52
1.17 The antigen, Ov-47 52
2 CHAPTER TWO 54
2.1 Rationale 54
2.2 Hypotheses 54
2.3 Overall Objective 54
2.4 Specific Objectives 55
3 CHAPTER THREE 56
STUDY POPULATIONS, MATERIALS AND METHODS 56
3.1 Reagents 56
3.2 Plastic and glassware 56
3.3 Study design and subject group composition 56
3.4 Ethical considerations and participant recruitment 58
3.5 Human and Cattle Sample Collection 59
3.5.1 Collection of human samples 59
3.5.2 Collection of bovine samples 63
3.6 Nodular released products, excretory-secretory products, worm surface proteins and worm total protein extracts 64
3.6.1 Nodular released products 64
3.6.2 Excretory-excretory products 64
3.6.3 Worm surface proteins 64

3.6.4 Total protein extract 64
3.7 Sequence and phylogenetic analyses 65
3.8 Immuno-informatic analyses and peptide synthesis 66
3.9 Intrinsic disordered regions and coiled-coil domains prediction 66
3.10 Serological assays for peptides and peptide cocktails 67
3.11 Cloning, mass eexpression and purification of Ov58GPCR-ECD 67
3.12 Mass spectrometry to confirm protein sequence 68
3.13 SDS PAGE analyses 69
3.14 Generation of polyclonal antibodies 69
3.14.1 Generation of anti-peptide antibodies 69
3.14.2 Generation of anti Ov58GPCR-ECD antibodies 69
3.15 Immunological Characterization of Ov58GPCR-ECD 70
3.15.1 Total serum IgG and IgG subclass ELISA 70
3.15.2 Total urine IgG and IgG_4 ELISAs 71
3.15.3 Antigen-specific IgE ELISA 71
3.15.4 Antibody responses and compliance to ivermectin 72
3.16 Stage-specific expression 73
3.17 RNAi experiments 74
3.17.1 siRNA design, synthesis for β-tubulin gene and gene knockdown 74
3.17.2 siRNA design, synthesis for Ov58GPCR gene and gene knockdown 75
3.17.3 Effects of siRNA soaking on motility of adult male worms 75
3.17.4 Measurement of the mRNA expression of Ov58GPCR 76
3.18 Data analyses 77
3.19 Protein selection for vaccine preparation 79
3.20 Linear B-cell epitope prediction. 79
3.21 Cytotoxic T lymphocytes (CTL) epitope prediction. 80
3.22 Helper T-cell (HTL) epitope prediction. 80
3.23 Protein and epitope conservation in related nematodes 81
3.24 Construction of multi-epitope vaccine sequence. 81
3.25 IFN-γ inducing epitope prediction 81
3.26 Antigenicity and allergenicity prediction of the designed vaccine peptide 82

3.27 Physiochemical properties and solubility prediction. 82
3.28 Secondary structure prediction. 83
3.29 Tertiary structure prediction. 83
3.30 Refinement of the Tertiary Structure 83
3.31 Tertiary structure validation 84
3.32 Discontinuous B-cell epitope prediction 84
3.33 Molecular docking of designed chimeric protein with TLR4 85
3.34 *In silico* cloning optimization of designed vaccine candidate 86
3.35 Immune Simulation of Chimeric vaccine candidate 86
4 CHAPTER FOUR 88
RESULTS 88
PART ONE: Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of *Onchocerca volvulus* (Paper published in *PLoS ONE* journal) 88
4.1 Study communities and population 88
4.1.1 The onchocerciasis-endemic communities 88
4.1.2 The onchocerciasis-near elimination communities (Bandjoun HD) 89
4.2 Parasitological indices and adherence to Ivermectin 89
4.2.1 The Muyuka Health District 89
4.2.2 The Mbonge Health District 90
4.2.3 The Bandjoun Health District 91
4.3 Ov58 is a conserved GPCR in nematodes 92
4.4 The extracellular domain (ECD) of Ov58GPCR harbors antigenic features 95
4.5 Predicted synthetic peptide cocktails exhibit potential for use in assessing success of CDTI programs 97
4.6 Ov58GPCR contains intrinsically disordered regions and coiled-coil domains ... 100
4.7 Bacterially-expressed and purified Ov58GPCR-ECD revealed predominantly monomeric but also dimeric forms 103
4.8 MALDI-TOF analysis confirmed that both the prominent and faint bands were different form of the Ov58ECD peptide 105
4.9 The humoral response to Ov58GPCR-ECD divulges its diagnostic potentials 106
4.10 IgG subclass responses in infected and endemic normals are similar 108

4.11 Total IgE and IgG subclasses but not total IgG responses to Ov58GPCR-ECD negatively and significantly correlated with treatment compliance 109

4.12 Urine anti-Ov58GPCR-ECD antibodies did not discriminate between actively-infected and control subjects..... 111

4.13 Ov58GPCR expression is activated in larvae and adult parasites stages 112

4.14 siRNA was successful in knocking down the genes for *Ovβ-tubulin* and *Ov58GPCR* 115

4.15 Protein sequences are expressed predominantly in the L3 larvae or microfilariae 118

4.16 Proteins contain several linear B-cell epitopes 118

4.17 Cytotoxic T Lymphocytes (CTL) were predicted in the selected proteins..... 119

4.18 Selected proteins were predicted to contain helper T Lymphocytes (HTL) epitopes prediction 119

4.19 Selected proteins and predicted epitopes are conserved in related nematodes..... 119

4.20 The multi-epitope subunit vaccine candidate has 599 amino acids..... 122

4.21 The designed chimeric vaccine candidate has several IFN-γ inducing epitopes... 122

4.22 The chimeric vaccine candidate is antigenic but non-allergenic 123

4.23 The designed protein has a molecular weight of 62.3 and is soluble upon expression 123

4.24 The chimeric vaccine candidate is made of predominantly of coils..... 124

4.25 The predicted 3 D structure had a good topology based on the TM score 125

4.26 Tertiary structure refinement improved on the predicted 3D structure 126

4.27 The refined 3D structure had favourable structural characteristics 126

4.28 The predicted 3D structure had several amino acids in conformational epitopes . 127

4.29 Molecular docking of the chimeric vaccine with TLR4 predicted efficient binding 128

4.30 The codon optimized construct for the vaccine candidate was generated..... 129

4.31 Immune simulation predicted high levels of IgM, IgG1+IgG2 and IFNγ 129

5 CHAPTER FIVE 131

DISCUSSION, CONCLUSIONS, PERSPECTIVES AND RECOMMENDATIONS131

4.1 Discussion..... 131

4.2 Conclusions..... 149

4.3 Perspectives 151

4.4 Recommendations..... 151

APPENDICES 179